Search Results 51-60 of 21336 for anti-TNF drugs

1. Adalimumab-Aacf (Subcutaneous Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

2. Adalimumab-Bwwd (Subcutaneous Route) Proper Use - Mayo Clinic

   This medicine comes with a Medication Guide and patient instructions. Read and follow these instructions carefully. Ask your doctor if you have any questions.

3. Adalimumab-Afzb (Subcutaneous Route) Precautions - Mayo Clinic

   Do not take other medicines unless they have been discussed with your doctor. Using abatacept (Orencia®) or anakinra (Kineret®) together with this medicine may ...

4. Adalimumab-Bwwd (Subcutaneous Route) Side Effects - Mayo Clinic

   Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

5. Adalimumab-Fkjp (Subcutaneous Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

6. Adalimumab-Aqvh (Subcutaneous Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

7. Weekend Wellness: Ankylosing spondylitis symptom changes hard to predict - Mayo Clinic News Network

   When these symptoms are persistent, treatment usually involves medications known as TNF blockers. ... Examples of these medications include adalimumab, etanercept ...

8. Etanercept-Szzs (Subcutaneous Route) Before Using - Mayo Clinic

   Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

9. Rheumatoid Arthritis Clinical Trials - Mayo Clinic Research

   ... treatment with modifying antirheumatic drugs (DMARDs) or anti-TNF alpha agents. Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis ...

10. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

    * Must have failed anti-TNF treatment for HS. * To be eligible for the Sub-study, participants must be naïve to biologic therapy for treatment of HS.